Disclosures for "First Randomized Controlled Trial of Responsive Thalamic Stimulation for Treatment of Idiopathic Generalized Epilepsy with Generalized Tonic Clonic Seizures: The RNS System NAUTILUS Trial 12- and 18-month Data"
-
Dr. Morrell has received personal compensation for serving as an employee of NeuroPace. Dr. Morrell has stock in NeuroPace. The institution of Dr. Morrell has received research support from National Institutes of Health.
-
Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace. Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuropace. Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Federal Public Defender - District of Kansas. Dr. Landazuri has received publishing royalties from a publication relating to health care.
-
The institution of Dr. Crudele has received research support from Neuropace. The institution of Dr. Crudele has received research support from Rapport Pharmaceuticals .
-
Dr. Burdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Catalyst. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for NeuroPace. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Burdette has received research support from Longboard. The institution of Dr. Burdette has received research support from NeuroPace.